Cantor Fitzgerald Reiterates “$9.00” Price Target for Endo International PLC (ENDP)
Endo International PLC (NASDAQ:ENDP) (TSE:ENL) has been assigned a $9.00 price objective by stock analysts at Cantor Fitzgerald in a research note issued to investors on Monday. The brokerage currently has a “hold” rating on the stock. Cantor Fitzgerald’s price objective indicates a potential upside of 53.06% from the stock’s current price.
A number of other research firms have also recently issued reports on ENDP. Oppenheimer Holdings Inc. reissued a “hold” rating on shares of Endo International PLC in a research report on Sunday, July 23rd. Royal Bank Of Canada set a $15.00 price objective on Endo International PLC and gave the company a “hold” rating in a research report on Sunday, July 16th. BidaskClub raised Endo International PLC from a “sell” rating to a “hold” rating in a research report on Wednesday, July 19th. Zacks Investment Research cut Endo International PLC from a “hold” rating to a “sell” rating in a research report on Tuesday, July 11th. Finally, Deutsche Bank AG reduced their price objective on Endo International PLC from $18.00 to $15.00 and set a “buy” rating for the company in a research report on Friday, July 7th. Four research analysts have rated the stock with a sell rating, fifteen have issued a hold rating and five have issued a buy rating to the stock. Endo International PLC currently has a consensus rating of “Hold” and an average price target of $12.64.
Endo International PLC (NASDAQ:ENDP) traded up 3.656% during trading on Monday, reaching $6.095. The company had a trading volume of 13,171,744 shares. Endo International PLC has a 12 month low of $5.77 and a 12 month high of $20.59. The firm’s market capitalization is $1.36 billion. The stock has a 50 day moving average price of $8.31 and a 200 day moving average price of $10.27.
Endo International PLC (NASDAQ:ENDP) (TSE:ENL) last released its quarterly earnings data on Tuesday, August 8th. The company reported $0.93 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.74 by $0.19. The firm had revenue of $875.73 million during the quarter, compared to analysts’ expectations of $832.66 million. Endo International PLC had a positive return on equity of 37.58% and a negative net margin of 126.93%. The business’s revenue for the quarter was down 4.9% on a year-over-year basis. During the same quarter last year, the firm earned $0.86 earnings per share. On average, equities research analysts predict that Endo International PLC will post $3.52 earnings per share for the current year.
ILLEGAL ACTIVITY NOTICE: This report was first posted by American Banking News and is the property of of American Banking News. If you are reading this report on another domain, it was stolen and republished in violation of international copyright law. The original version of this report can be read at https://www.americanbankingnews.com/2017/10/30/cantor-fitzgerald-reiterates-9-00-price-target-for-endo-international-plc-endp.html.
In other Endo International PLC news, COO Terrance J. Coughlin acquired 20,000 shares of the company’s stock in a transaction dated Thursday, August 10th. The shares were acquired at an average cost of $7.70 per share, for a total transaction of $154,000.00. Following the completion of the purchase, the chief operating officer now owns 181,369 shares of the company’s stock, valued at approximately $1,396,541.30. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Paul Campanelli acquired 6,500 shares of the company’s stock in a transaction dated Monday, August 14th. The stock was acquired at an average price of $7.71 per share, for a total transaction of $50,115.00. Following the completion of the purchase, the chief executive officer now directly owns 213,620 shares of the company’s stock, valued at approximately $1,647,010.20. The disclosure for this purchase can be found here. Insiders bought 36,000 shares of company stock worth $279,460 over the last quarter. 0.50% of the stock is currently owned by corporate insiders.
Several institutional investors have recently bought and sold shares of ENDP. Thrivent Financial For Lutherans bought a new position in shares of Endo International PLC in the first quarter worth about $1,338,000. Amalgamated Bank increased its stake in Endo International PLC by 2.0% during the first quarter. Amalgamated Bank now owns 32,357 shares of the company’s stock valued at $361,000 after acquiring an additional 619 shares during the period. Teachers Retirement System of The State of Kentucky increased its stake in Endo International PLC by 30.0% during the first quarter. Teachers Retirement System of The State of Kentucky now owns 36,400 shares of the company’s stock valued at $406,000 after acquiring an additional 8,400 shares during the period. Capstone Asset Management Co. increased its stake in Endo International PLC by 3.1% during the second quarter. Capstone Asset Management Co. now owns 32,035 shares of the company’s stock valued at $358,000 after acquiring an additional 960 shares during the period. Finally, Meeder Asset Management Inc. increased its stake in Endo International PLC by 1.4% during the second quarter. Meeder Asset Management Inc. now owns 48,699 shares of the company’s stock valued at $544,000 after acquiring an additional 677 shares during the period. Institutional investors and hedge funds own 90.29% of the company’s stock.
About Endo International PLC
Endo International PLC, formerly Endo Health Solutions Inc is a specialty healthcare solutions company focused on branded and generic pharmaceuticals, devices and services. The Company has a portfolio of branded pharmaceuticals that includes brands, such as Lidoderm, Opana ER, Voltaren Gel, Percocet, Frova, Supprelin LA, Vantas, Valstar and Fortesta Gel.
Receive News & Ratings for Endo International PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Endo International PLC and related companies with MarketBeat.com's FREE daily email newsletter.